PharmaMar takes fresh legal action in EU Aplidin appeal

10 January 2019

Madrid, Spain-based PharmaMar (MSE: PHM) has launched a legal action against the European Commission to try to secure European Medicines Agency (EMA) approval for Aplidin (plitidepsin).

Last year the EMA did not recommend approval of the therapy, which has been designated an orphan drug since 2004 for the treatment of multiple myeloma. That decision is already being appealed in the European Court of Justice.

Pharma Mar is lodging a complaint with the Court which alleges “breaches in impartiality, good administration, equal treatment and the right of defence” during the approval process for the drug.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK